InvestorWire NewsRoom

Article

Lexaria Bioscience Corp. (NASDAQ: LEXX) is Changing Absorption of Fat-Soluble Compounds Through Patented DehydraTECH(TM) Technology
September 8, 2021

Lexaria Bioscience Corp. (NASDAQ: LEXX) is Changing Absorption of Fat-Soluble Compounds Through Patented DehydraTECH(TM) Technology

  • Lexaria Bioscience Corp. and its patented DehydraTECH technology promote a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro, and human clinical testing
  • DehydraTECH is sub-licensed to other companies in select countries, and is in close collaboration with the largest R&D organization in Canada, the National Research Council, since January 2017
  • The technology is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter (“OTC”) capsules, pills, tablets, and oral suspensions 
  • DehydraTECH-enabled drugs offer multiple benefits, including faster delivery, increased bioavailability, increased brain absorption, improved drug potency, reduced administration costs, and masking unwanted taste without the use of additional sweeteners.

As an innovator of drug delivery methods, Lexaria Bioscience (NASDAQ: LEXX) and its patented DehydraTECH are improving the speed and efficiency of orally delivered fat-soluble active molecules and drugs. Lexaria Bioscience is advancing its IP for transforming existing consumer products and medications that may improve availability and bioavailability. DehydraTECH promotes a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro, and human clinical testing.

Lexaria Bioscience operates four subsidiary companies focused on different commercial opportunities within their respective industries – Lexaria Pharma Corp., Lexaria Nicotine Corp. (16.67% owned by Altria Ventures Inc.), Lexaria Hemp Corp., and Lexaria Canpharm Corp. The DehydraTECH technology is also sub-licensed to other companies in select countries. The Company also has a collaborative research agreement with the National Research Council (“NRC”), Canada’s premier research and technology organization.

Lexaria Pharma Corp. – investigates new products for high blood pressure (hypertension), antiviral therapy, and other drug classes.

Lexaria Nicotine Corp. – investigates oral non-combusted tobacco-derived nicotine product formats.

Lexaria Hemp Corp. – pursues business-to-business (“B2B”) opportunities, with cannabinoids like cannabidiol (“CBD”).

Lexaria Canpharm Corp. – operates a state-of-the-art Health Canada-licensed laboratory that can develop novel psychotropic cannabinoid formulations for commercialization in sectors where it is federally legal.

The DehydraTECH technology is suitable for use with a wide range of product formats. These include pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter (“OTC”) capsules, pills, tablets, and oral suspensions. The technology was specifically designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients into a more easily absorbable format, allowing them to enter the bloodstream more quickly and effectively.

The use of DehydraTECH-enabled drugs or consumer products offers the following benefits:

  • Speeds up delivery: effects can be felt by consumers in a matter of minutes
  • Increases bioavailability: more effective at delivering drug or product into the consumer’s bloodstream
  • Increases brain absorption: animal testing has suggested significant improvement in the quality of the drug delivered across the blood-brain barrier
  • Improves drug potency: more of the ingested product is made available to the body, requiring lower dosages to achieve the desired effects
  • Reduces drug administration costs: lower dosages mean overall lower drug costs
  • Masks unwanted taste: technology eliminates or reduces the need for sweeteners

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to ten times, reducing the onset time from one to two hours to just minutes – masking unwanted tastes. The technology will be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), and nicotine.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).